Primary Prevention Program

Not Applicable

Completed

• Conditions: Primary Prevention of Cardiovascular Disease
• Interventions: Behavioral: extended counseling

• Registration Number: NCT03927196
• Lead Sponsor: National Research Center for Preventive Medicine

Brief Summary

A systematic collection of retrospective and prospective data based on non-intervention patient observation, aimed to assess the risks, course and outcomes of a disease or a group of diseases:

* the retrospective part: database of patients with cardiovascular risks;

* the prospective part: observation of patients in the real medical practice

Detailed Description

The research program will have two parts:

Stage1: identification of patients with moderate, high and very high cardiovascular risks, not having diseases of atherosclerotic genesis and requiring lipid-lowering drugs.

Stage 2: a prospective observation of patients receiving primary medical prophylaxis of CVD with atorvastatin

Study Timeline

• Study Start: 2018-06-21
• Study First Submitted: 2019-02-12
• Study First Submitted QC: 2019-04-24
• Study First Posted: 2019-04-25
• Primary Completion: 2019-08-28
• Study Completion: 2019-08-28
• Status Verified: 2019-09
• Last Update Submitted: 2019-09-09
• Last Update Posted: 2019-09-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2912

Inclusion Criteria

Men and women 40-65 years old with the presence of:

• moderate cardiovascular risk (<5% but ≥1% on a SCORE scale) and cholesterol level LDL ≥3.0 mmol / l, in which the target is not reached during the improvement of lifestyle level of cholesterol-LDL, and the attending physician considers appropriate the appointment lipid-lowering drugs (statins), or
• high cardiovascular risk (≥5% but <10% on a SCORE scale) and cholesterol level LDL ≥ 2.5 mmol / l, or
• very high cardiovascular risk (≥10% on the SCORE scale) and cholesterol-LDL ≥1.8mmol / l, or
• atherosclerotic stenosis of the brachiocephalic arteries> 50% in the absence cerebrovascular diseases and the level of cholesterol-LDL ≥1.8 mmol / l, which do not have contraindications to taking statins and not taking drugs of this group in currently.

Exclusion Criteria

• The presence of the following clinically significant events in anamnesis: myocardial infarction, stroke, myocardial infarction
• The presence of the following diseases at the time of statin administration: ischemic heart disease; heart failure; atherosclerotic disease of peripheral arteries; atherosclerotic stenosis of the brachiocephalic arteries in the presence of cerebrovascular disease; chronic renal failure with creatinine clearance <30 ml / min; liver disease with an increase in AST and ALT levels of more than 3 times, compared to the upper limit of normal; history of muscular or neuromuscular diseases, with elevated CPK; alcoholism, oncological, mental and other severe concomitant diseases; intolerance to statins in anamnesis; use of other lipid-modifying agents.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
extended statin counseling group	extended counseling	Extended statins counseling. Patients are handed out information leaflets on the correction of risk factors, SMS reminders.

Primary Outcome Measures

Name	Time	Method
Change in the percentage of patients who achieved target LDL cholesterol level depending on the level of cardiovascular risk from baseline and 12 months	12 months	The primary objective of this study is to assess the influence of routing and extended statin counseling of patients with cardiovascular risk factors on the change in the percentage of patients who achieved target LDL cholesterol level from baseline through 12 months

Secondary Outcome Measures

Name	Time	Method
Assess the effect of routing and extended statin counseling on changes in treatment adherence	Baseline and Month 12	The method used to measure adherence included the Morisky Medication Adherence Scale (MMAS - 4).; Morisky Medication Adherence Scale is 4- item self-reported scale measuring medication taking behavior. Scores are transformed to a range of 0-4, in which higher scores reflect better adherence
Change from baseline in blood pressure (mm Hg)	Baseline, Month 3, Month 6 and Month 12	To evaluate the impact of standard and extended counseling on change of CVD risk factors (blood pressure). Measurement of blood pressure (mm Hg) at baseline and after 3,6,12 months
Change from baseline in lipid levels (mmol/l)	Baseline, Month 3, Month 6 and Month 12	To evaluate the impact of extended statin counseling on change of CVD risk factors (lipid levels) in patients with moderate, high and very high risk. Measurement of lipid levels at baseline and after 3,6,12 months
Impact of standard and extended counseling on statin therapy adherence	Baseline and Month 12	The method used to measure adherence was KAP test. KAP test is the specially designed questionnaire for this study includes 14 questions, in patients with hyperlipidemia. KAP test summary score is an assessment of patients' knowledge about high cholesterol, their attitude to this problem and the application of this knowledge. Higher scores reflect better indicators of knowledge, attitudes and practices

Trial Locations

Locations (5)

Deputy Chief Medical Officer for Prevention at the Center for Medical Prevention; 🇷🇺 Astrakhan, Russian Federation

Nizhny Novgorod Regional Center for Medical Prevention; 🇷🇺 Nizhny Novgorod, Russian Federation

Regional Center for Medical Prevention; 🇷🇺 Novosibirsk, Russian Federation

Republican Center for Medical Prevention of the Republic of Bashkortostan; 🇷🇺 Ufa, Russian Federation

Samara Regional Center for Medical Prevention; 🇷🇺 Samara, Russian Federation